Satellos Bioscience is building its case for a Duchenne muscular dystrophy pill with data in adult patients ahead of a potentially pivotal readout in children later this year. The Canadian biotech’s Phase 2 study in …
Source: Endpoints News
You may also like
Stem Cell Therapy Shows Promise in First Human...
Ag Genomics Begins to Bear Fruit
StockWatch: Insilico Projects Profit, Revenue Leaps as...
Macrophage Membrane-Derived Nanoparticles Shows...
[Podcast] From Protocol to Patient: Inside Clinical...
KKR-backed Allyntra debuts to serve medtech industry...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.